XXXXXXXXX XXXXXXXX KOMISE (XX) 2021/709
xx dne 29.&xxxx;xxxxx 2021
x&xxxx;xxxxxxxx X-xxxxxxxx-xxxxxxxxxxxxxxxxx xxxxxxxxxxx x&xxxx;Xxxxxxxxxxx coli XXXX 80212&xxxx;xxxx xxxxxxxxx xxxxx xxx xxxxxxx xxxxx zvířat
(Text x&xxxx;xxxxxxxx xxx XXX)
XXXXXXXX KOMISE,
s ohledem xx Smlouvu x&xxxx;xxxxxxxxx Xxxxxxxx xxxx,
x&xxxx;xxxxxxx xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (ES) x.&xxxx;1831/2003 xx xxx 22.&xxxx;xxxx&xxxx;2003 x&xxxx;xxxxxxxxxxx látkách xxxxxxxxxxx xx xxxxxx xxxxxx&xxxx;(1), x&xxxx;xxxxxxx xx xx.&xxxx;9 xxxx.&xxxx;2 xxxxxxxxx nařízení,
vzhledem x&xxxx;xxxxx xxxxxxx:
(1) |
Xxxxxxxx (XX) x.&xxxx;1831/2003 stanoví xxxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxx xx xxxxxx xxxxxx x&xxxx;xxxxxx a postupy, xx xxxxxxx xxxxxxx xx xxxxxxxx xxxxxxx. |
(2) |
X&xxxx;xxxxxxx x&xxxx;xxxxxxx&xxxx;7 xxxxxxxx (ES) x.&xxxx;1831/2003 xxxx xxxxxx xxxxxx x&xxxx;xxxxxxxx L-histidin-monohydrochloridu monohydrátu. Xxxx xxxxxx xxxx xxxxxx xxxxx x&xxxx;xxxxx x&xxxx;xxxxxxxxx xxxxxxxxxxxx xxxxx xx.&xxxx;7 xxxx.&xxxx;3 uvedeného xxxxxxxx. |
(3) |
Xxxxxx se xxxx xxxxxxxx X-xxxxxxxx-xxxxxxxxxxxxxxxxx monohydrátu x&xxxx;Xxxxxxxxxxx xxxx XXXX 80212&xxxx;xxxx xxxxxxxxx xxxxx xxx xxxxxxx xxxxx xxxxxx xx xxxxxxxxx xx kategorie xxxxxxxxxxx xxxxx „xxxxxxxx xxxxxxxxx xxxxx“. |
(4) |
Xxxxxxxx xxxx xxx xxxxxxxxxx potravin (xxxx xxx „xxxx“) xxxxxx xx svém xxxxxxxxxx xx xxx 30.&xxxx;xxxx&xxxx;2020&xxxx;(2) x&xxxx;xxxxxx, xx xx xxxxxxxxxx xxxxxxxx xxxxxxx X-xxxxxxxx-xxxxxxxxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxxxxxxxxx xxxx XXXX 80212 xxxx xxx xxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxx cílových xxxxx xxxxxxxxxx xxxxxx na xxxxxx xxxxxx, zdraví xxxxxxxxxxxx xxx na xxxxxxx xxxxxxxxx. Xxxxx xxx o bezpečnost uživatele xxxxxxxxx xxxxx, xxxx xxxxx, xx X-xxxxxxxx-xxxxxxxxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxxxxxxxxx coli XXXX 80212 xx xxxxx xxxxxxxxxxxxxxx xxxx x&xxxx;xx xxxxxxxx riziko xxxxxxxx xxxxxxxxxxx xxx xxxxxxxxxx. Proto xx xxxx xxx xxxxxxx xxxxxx xxxxxxxx xxxxxxxx, xxx xx xxxxxxxxx xxxxxxxxxxx účinkům této xxxxxxxxx xxxxx xx xxxxxx xxxxxx, zejména xxxxx jde x&xxxx;xxxxxxxxx xxxx doplňkové xxxxx. Xxxx xxxx dospěl x&xxxx;xxxxxx, že L-histidin-monohydrochlorid xxxxxxxxxx z Escherichia coli XXXX 80212 xx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxxxx X-xxxxxxxx pro xxxxxx xxxxxx x&xxxx;xx x&xxxx;xxxxx účinnosti x&xxxx;xxxxxxxxxxx xx xxxx xxxxxxxxx xxxxx měla xxx xxxxxxxx xxxx rozkladem x&xxxx;xxxxxxx. Xxxx xxxxxxxxxx xxxxxxxx xxxxxxxxx xx xxxxxxxxxxxx xx xxxxxxx xx xxx za xxxxx. Xxxx také xxxxxx zprávu x&xxxx;xxxxxx xxxxxxx xxxxxxxxx xxxxx xxxxxxx xx xxxxx, xxxxxx xxxxxxxxxx referenční xxxxxxxxx xxxxxxx nařízením (XX) č. 1831/2003. |
(5) |
Posouzení xxxxxxx xxxxx xxxxxxxxx, xx xxxxxxxx xxx xxxxxxxx xxxxxxxxx x&xxxx;xxxxxx&xxxx;5 xxxxxxxx (XX) x.&xxxx;1831/2003 xxxx xxxxxxx. Proto xx xxxx xxx xxxxxxxxx xxxxxxx xxxxx povoleno xxxxx xxxxxxx xxxxxx xxxxxxxx. |
(6) |
Xxxxxxxx xxxxxxxxx tímto xxxxxxxxx xxxx v souladu xx xxxxxxxxxxx Stálého xxxxxx xxx rostliny, xxxxxxx, xxxxxxxxx x&xxxx;xxxxxx, |
XXXXXXX XXXX XXXXXXXX:
Článek 1
L-histidin-monohydrochlorid xxxxxxxxxx z Escherichia xxxx XXXX 80212 xxxxxxxxxxxxx v příloze, xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx „xxxxxxxx doplňkové xxxxx“ a funkční xxxxxxx „xxxxxxxxxxxxx, xxxxxx soli x&xxxx;xxxxxxx“, xx povoluje xxxx xxxxxxxxx xxxxx xxxxx xxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxx xxxxxxx.
Xxxxxx&xxxx;2
Xxxx xxxxxxxx xxxxxxxx x&xxxx;xxxxxxxx xxxxxxxx xxxx xx xxxxxxxxx x&xxxx;Xxxxxxx xxxxxxxx Xxxxxxxx xxxx.
Xxxx xxxxxxxx xx xxxxxxx x&xxxx;xxxxx xxxxxxx x&xxxx;xxxxx použitelné ve xxxxx xxxxxxxxx státech.
V Bruselu xxx 29.&xxxx;xxxxx 2021.
Za Xxxxxx
xxxxxxxxxxx
Xxxxxx XXX XXX XXXXX
(1)&xxxx;&xxxx;Xx. věst. L 268, 18.10.2003, x.&xxxx;29.
(2)&xxxx;&xxxx;XXXX Xxxxxxx 2020;18(11):6287.
XXXXXXX
Xxxxxxxxxxxxx číslo xxxxxxxxx xxxxx |
Xxxxx xxxxxxxx povolení |
Doplňková xxxxx |
Xxxxxxx, chemický xxxxxx, xxxxx, analytická xxxxxx |
Xxxx xxxx kategorie xxxxxx |
Xxxxxxxxx xxxxx |
Xxxxxxxxx xxxxx |
Xxxxxxxxx obsah |
Jiná xxxxxxxxxx |
Xxxxx xxxxxxxxx povolení |
||||||||||||||
mg/kg xxxxxxxxxxx xxxxxx x&xxxx;xxxxxx xxxxxxxx 12&xxxx;% |
|||||||||||||||||||||||
Xxxxxxxxx: xxxxxxxx xxxxxxxxx látky. Xxxxxxx xxxxxxx: xxxxxxxxxxxxx, xxxxxx xxxx a analogy. |
|||||||||||||||||||||||
3c352i |
— |
L-histidin-monohydrochlorid monohydrát |
Složení xxxxxxxxx xxxxx: Xxxxxx x&xxxx;xxxxxxxxxx xxxxxxx 98&xxxx;% L-histidin-monohydrochloridu xxxxxxxxxxx x 72&xxxx;% xxxxxxxxx x xxxxxxxxxx xxxxxxx 100 xxx xxxxxxxxx |
Xxxxxxx xxxxx zvířat |
— |
— |
— |
|
20.5.2031 |
||||||||||||||
Xxxxxxxxxxxxxxx xxxxxx xxxxx: X-xxxxxxxx-xxxxxxxxxxxxxxxx monohydrát x&xxxx;xxxxxxxxxx pomocí Escherichia xxxx KCCM 80212 Xxxxxxxx xxxxxx: C3H3N2-CH2-CH(NH2)-COΟΗ·ΗCl·Η2O Číslo XXX: 5934-29-2 Xxxxx XXXXXX: 211-438-9 |
|||||||||||||||||||||||
Analytická xxxxxx&xxxx;&xxxx;(1): Xxx xxxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxxx látce:
Xxx xxxxxxxxx xxxxxxxxx v premixech, xxxxxxx xxxxxxxxxx x&xxxx;xxxxxxx xxxxxxx:
Pro xxxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxxx xxxxx:
|
(1)&xxxx;&xxxx;Xxxxxxxx informace x&xxxx;xxxxxxxxxxxx xxxxxxxx xxx získat xx xxxxxxxxxxx stránce xxxxxxxxxx laboratoře: https://ec.europa.eu/jrc/en/eurl/feed-additives/evaluation-reports
(2) Expozice xx xxxxxxxxxx na xxxxxxx xxxxxxx endotoxinů x&xxxx;xxxxxxxxx xxxxxxxxx látky xxxxx xxxxxx xxxxxxxxx Xxxxxxxxx úřadem pro xxxxxxxxxx xxxxxxxx (EFSA Xxxxxxx 2015;13(2):4015); xxxxxxxxxx xxxxxx: Xxxxxxxx xxxxxxx 2.6.14 (xxxxxxxxxxx xxxxxxxxxx).